Gao Wei, a doctor of cell biology from Peking University, a former examiner of the China National Intellectual Property Administration, has patent agent and legal professional qualification certificates, and is a young top talent in Gusu intellectual property. He has rich practical experience in intellectual property management, drug patent application and layout, patent search analysis and risk screening, and intellectual property evaluation in business cooperation. The current head of intellectual property and senior director of Yangtze River Pharmaceutical Group is fully responsible for the patent layout and protection of the group's innovative and generic drug development. Before joining Yangtze River, he served as the head of intellectual property for local biopharmaceutical companies and Du Bio, the head of intellectual property risk management for Xinda Bio, a foreign patent agent for Jijia Intellectual Property, and a patent examiner. During my time at Xinda Biotechnology, I have been deeply involved in the intellectual property evaluation and commercial cooperation negotiations of dozens of BD projects, and have a unique understanding of intellectual property risk management in drug transactions. Jijia has represented numerous domestic innovative entities in export cases and is familiar with patent regulations and application practices in countries such as the United States, Europe, Japan, South Korea, Australia, and India.